Viropro, Inc. to Unlock Value from its Biosimilars Portfolio MarketWatch (press release) The starting line-up and portfolio consists of sophisticated biosimilar molecules such as Ranibizumab (biosimilar of Lucentis(R)), Trastuzumab (-Herceptin(R)), Rituximab (-Rituxan(R)), Bevacizumab (-Avastin(R)), Infliximab (-Remicade(R)) and Etanercept ... |
